Dynamics of Neutralizing Antibodies and Binding Antibodies to Domains of SARS-CoV-2 Spike Protein in COVID-19 Survivors

Abstract

Neutralizing antibody level is used to predict immune protection against SARS-CoV-2 infection. Spike protein of SARS-CoV-2 is a major target for virusneutralizing antibody. A number of neutralizing epitopes were mapped on receptor binding domain (RBD) and N-terminal domain (NTD) of S1 subunit of the spike. Anti-SARS-CoV-2 antibody usually decreases over time after recovery. Level of neutralizing antibody and binding antibody to several domains from COVID-19 recovered patients were observed longitudinally in this study. Sequentially collected serum samples from 35 patients demonstrated both similar and different trends of neutralizing antibodies versus binding antibodies to each domain. Twenty-three individuals showed similarly decreasing pattern of neutralizing titer, binding antibodies to RBD, NTD, fusion protein (S2) and nucleocapsid (NP). Interestingly, eight individuals had stably high neutralizing titer (≥320) for 3-12 months, while their binding antibodies to RBD, NTD and NP rapidly decreased. Moreover, their binding antibodies to S2 were stable over time similar to the persistence of neutralizing antibody levels. The longer-lasting antibody to S2 suggested an anamnestic response to cross-reactive epitopes from previous infections with other related coronaviruses. These data indicate a difference in kinetics and longevity of antibodies to various domains and epitopes of the SARS-CoV 2 proteins. A better understanding in this difference may help improve vaccine design to induce long-lasting immunity to COVID-19.

Long-lasting neutralizing antibodies and T cell response after the third dose of mRNA anti-SARS-CoV-2 vaccine in multiple sclerosis

“…This phenomenon could relay first to the mechanism of actions of DMTs: the majority of patients showing this peculiar pattern were under the immunoreconstitution therapies alemtuzumab and cladribine, in which both T and B cells were depleted and then reconstitute toward a less inflammatory phenotype. Furthermore, the increase in IFNγ production can contribute to Ab affinity maturation, therefore augmenting Abs neutralizing efficacy ( 39 ).…”

Understanding the SARS-CoV-2 Virus Neutralizing Antibody Response: Lessons to Be Learned from HIV and Respiratory Syncytial Virus

“…These vaccines successfully reduced SARS-CoV-2-associated mortality, but, as with natural disease, antibody-associated immunity to subsequent infection was short-lived; the longevity of T cell-based immunity and its potential role(s) in the protection from subsequent infection are not fully understood yet. While vaccination importantly provides amelioration of disease symptoms, successive immunizations (up to five, to date) did not improve the longevity of protection, and even the combination of post-infection immunity and vaccination gave a similarly short-lived immunity to infection [ 1 , 2 , 3 , 4 ]. Thus, the human population as a whole is still at risk from an infection that ranges from the subclinical to a variable morbidity that has serious personal and economic impacts by requiring time away from the workplace.…”